Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Consensus Rating of "Hold" from Analysts

Key Points

• Analysts have assigned Agios a consensus rating of “Hold” from 11 firms (1 sell, 4 hold, 6 buy), with an average 1‑year price target of $41.78.
• Analyst views and targets have recently moved in both directions — Citigroup raised its target to $46 and kept a buy rating, Goldman Sachs nudged its target to $32 with a neutral rating, while HC Wainwright and Bank of America trimmed their targets to $50 and $41 respectively.
• Shares opened at $25.32 with a market cap of $1.48B and a 52‑week range of $22.24–$46.00, and insiders sold a total of 15,582 shares (~$520k) over the last three months under Rule 10b5‑1 plans, leaving insiders owning 4.30% of the stock.

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) have been assigned an average recommendation of "Hold" from the eleven research firms that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $41.7778.

AGIO has been the topic of several research reports. The Goldman Sachs Group boosted their target price on Agios Pharmaceuticals from $28.00 to $32.00 and gave the company a "neutral" rating in a research note on Wednesday, April 1st. Citigroup lifted their price objective on shares of Agios Pharmaceuticals from $38.00 to $46.00 and gave the company a "buy" rating in a report on Thursday, March 5th. Wall Street Zen raised shares of Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Sunday, March 22nd. Bank of America decreased their target price on shares of Agios Pharmaceuticals from $44.00 to $41.00 and set a "buy" rating for the company in a research report on Tuesday. Finally, HC Wainwright lowered their price target on shares of Agios Pharmaceuticals from $65.00 to $50.00 and set a "buy" rating on the stock in a research note on Monday, April 20th.

Agios Pharmaceuticals Price Performance

AGIO stock opened at $25.32 on Friday. The stock has a market capitalization of $1.48 billion, a P/E ratio of -3.56 and a beta of 0.79. Agios Pharmaceuticals has a fifty-two week low of $22.24 and a fifty-two week high of $46.00. The business has a 50-day moving average of $30.00 and a 200-day moving average of $31.46.

Insider Buying and Selling

In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 3,262 shares of the firm's stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $34.71, for a total value of $113,224.02. Following the completion of the transaction, the insider directly owned 46,829 shares in the company, valued at $1,625,434.59. This trade represents a 6.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Cecilia Jones sold 3,141 shares of the company's stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $34.71, for a total value of $109,024.11. Following the sale, the chief financial officer owned 54,998 shares in the company, valued at approximately $1,908,980.58. This represents a 5.40% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 15,582 shares of company stock worth $520,405 over the last three months. Company insiders own 4.30% of the company's stock.

Hedge Funds Weigh In On Agios Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. T. Rowe Price Investment Management Inc. acquired a new position in Agios Pharmaceuticals during the fourth quarter worth $25,000. Assetmark Inc. lifted its stake in Agios Pharmaceuticals by 37.9% in the fourth quarter. Assetmark Inc. now owns 1,317 shares of the biopharmaceutical company's stock valued at $36,000 after acquiring an additional 362 shares during the last quarter. NewEdge Advisors LLC bought a new position in shares of Agios Pharmaceuticals in the 1st quarter valued at about $40,000. First Horizon Corp acquired a new position in shares of Agios Pharmaceuticals during the 3rd quarter worth about $45,000. Finally, Caitong International Asset Management Co. Ltd acquired a new position in shares of Agios Pharmaceuticals during the 4th quarter worth about $49,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company's scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios's lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.